FT : Some wild speculation about Ukrenergo bond prices

Some wild speculation about Ukrenergo bond prices
Premium puzzles

Mark Weidemaier, Ugo Panizza and Mitu Gulati are faculty at the University of North Carolina (law), the University of Virginia (law) and the Geneva Institute (international economics), respectively.

About a month ago there was an announcement that a bondholder group had formed for the Ukrainian state-owned power company, Ukrenergo. The bond was guaranteed by the Ukrainian sovereign, and the core of the announcement was this (Alphaville’s emphasis below):

The Group wishes to make clear from the outset that, for the Group to support any restructuring or liability management transaction in relation to the Notes, such restructuring or transaction must deal with the Company’s indebtedness on a standalone basis and not as part of any contemplated restructuring of Ukraine’s sovereign indebtedness.

That’s well and good — of course, the holders of every bond want special treatment. But here’s the bit that got us and others interested. Upon the announcement, the market price of these bonds shot up roughly 30 per cent over the sovereign’s own bonds. That premium has since gone down, but the Ukrenergo still trades at about a 15 per cent premium over a comparable sovereign bond.

What the hell? What information was in the announcement that got the market so excited? We see no obvious explanation so, as we enjoy doing from time to time, we speculate.

First, some background. In July 2022, a few months after the onset of war with Russia, maturities for this bond and others issued by Ukraine were consensually extended until November 2024. Perhaps the hope was that the war would be over by late 2024. Going by the relative market prices of the Ukrenergo and Ukrainian sovereign bonds, everyone seems to have assumed at the time that this bond would be restructured on the same terms as other Ukrainian sovereign credits in any future postwar debt workout.

One might ask why the Ukrenergo bond with a sovereign guarantee would be treated the same as Ukrainian sovereign bonds. It is backed by two entities (the company and the sovereign) whereas vanilla sovereign bonds are backed by only the sovereign. Unless the company is just a bucket of bolts, its creditors should get more in a restructuring.

A possible answer is that the Ukrenergo bond has an “aggregated” collective action clause (CAC), which allows key terms like payment obligations to be modified in an aggregated vote of all holders of bonds with similar CACs. The threshold for such a modification is 75 per cent. At $825mn the Ukrenergo bond is relatively small — dwarfed by $20bn worth of Ukrainian bonds with aggregated CACs. The latter group can stick Ukrenergo bondholders with whatever treatment they accept for themselves. And that will be dictated by estimations by the IMF and others about how much postwar debt relief Ukraine will need.

In the midst of all this, why would this little Ukrenergo bond expect special treatment? Some wild speculations follow.

Sneaky-good contract terms?
Since we study contract provisions, our first assumption tends to be that a lawyer for creditors found an advantage in the bond documents. Or at least, some wonky language that might be plausibly argued to suggest the guarantee is stronger than realised. But we struggle to find anything in the Ukrenergo bond that offers bondholders special protection.

The Ukrenergo bond can be aggregated with all the others as long as its CAC has substantially the same terms as the others. And as best we can tell it is almost identical, except for referring to the guarantee. So it looks like these investors can be forced to vote along with the much larger group of Ukrainian sovereign bondholders.

And while the guaranteed bond has some confusing language — such as saying that the sovereign guarantor’s obligations will not be affected by a modification to the Ukrenergo bond — the sovereign is only on the hook for “all amounts payable by the issuer.” So, if those amounts are reduced via the CAC, so is the amount the sovereign must pay.

Strip the guarantee?
Could it be possible that bondholders want to get rid of the guarantee — perhaps believing that this will take them outside the umbrella of sovereign obligations that will have to be restructured?

Ukrenergo is hardly a thriving company. But perhaps it, like some other Ukrainian companies, benefits from some of the subsidies provided by European governments and the US, which understand the importance of keeping the lights on in Ukraine.

And perhaps holders of the Ukrenergo bond think the sovereign will allow them to escape the restructuring if they let it off the hook on the guarantee. It would improve the sovereign’s balance sheet a bit to remove the guarantee obligation. 

But really? Is that enough for the sovereign to let these bonds escape?

And what about those railway bonds?
As an aside, we note that bond prices for Ukraine’s state-owned railways also trade at a hefty premium over the sovereign’s bonds. As with the sovereign bonds, payments on these bonds were also postponed for two years in late 2022. 

Are the railways a good enough company to justify the pricing premium over Ukraine’s sovereign bonds? Have these state-owned companies somehow become profit machines during the war? Or is this pricing weirdness a function of bondholders hoping to get paid out of subsidies from the Europeans and Americans? (here and here)

If we are right in our wild speculations that these companies look good because they benefit from war subsidies, surely the subsidy providers will not be pleased to see their money passed on to holders of the Ukrenergo bonds. (Since we enjoy speculation, we picture the bondholder premia resulting from grabbing a share of the war subsidies being used to build a new wing on to someone’s mansion in the Hamptons.)

And if it will piss off the donors, can Ukraine really intend to play along? It needs every penny for defence and, later, reconstruction. There is something black in the lentils, as Mitu’s mom would say. No other moms could be reached for comment.

>>> US Research Calls I

Research Calls
  • Upgrades:
    • Avis Budget (CAR) upgraded to Buy from Neutral at Northcoast; tgt $155
    • Cincinnati Fincl (CINF) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $135
    • Foot Locker (FL) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $32
    • GoodRx (GDRX) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $10
    • HUYA (HUYA) upgraded to Buy from Neutral at BofA Securities; tgt $5.80
    • Laboratory Corp (LH) upgraded to Buy from Hold at Argus; tgt $250
    • Masimo (MASI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $160
    • Petrobras (PBR) upgraded to Buy from Hold at HSBC Securities; tgt $18
    • Tempur Sealy Int'l (TPX) upgraded to Buy from Hold at Loop Capital; tgt raised to $75
    • Walt Disney (DIS) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $135
  • Downgrades:
    • BigCommerce (BIGC) downgraded to Underperform from Neutral at BofA Securities; tgt lowered to $7.50
    • BWX Technologies (BWXT) downgraded to Hold from Buy at Truist; tgt lowered to $95
    • Canadian Pacific (CP) downgraded to Sector Perform from Sector Outperform at Scotiabank
    • Curtiss-Wright (CW) downgraded to Hold from Buy at Truist; tgt lowered to $240
    • Dave & Buster's (PLAY) downgraded to Mkt Perform from Outperform at Raymond James
    • Financial Inst. (FISI) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $19
    • Kinder Morgan (KMI) downgraded to Hold from Buy at Truist; tgt lowered to $20
    • McDonald's (MCD) downgraded to Hold from Buy at Argus
    • NIO (NIO) downgraded to Neutral from Buy at Mizuho; tgt $5.50
    • Rivian Automotive (RIVN) downgraded to Neutral from Buy at Mizuho; tgt $12
    • Scotts Miracle-Gro (SMG) downgraded to Mkt Perform from Strong Buy at Raymond James
    • Societe Generale (SCGLY) downgraded to Equal-Weight from Overweight at Morgan Stanley
    • Telus (TU) downgraded to Sector Perform from Sector Outperform at Scotiabank
    • Tesla (TSLA) downgraded to Neutral from Buy at Mizuho; tgt $195
  • Others:
    • Bank of America (BAC) initiated with an Accumulate at Phillip Securities
    • CS Disco (LAW) resumed with a Neutral from Overweight at JP Morgan; tgt $9
    • Healthpeak Properties (DOC) resumed with an Equal Weight at Wells Fargo; tgt $19
    • JPMorgan Chase (JPM) initiated with a Buy at Phillip Securities
    • Kinetik (KNTK) initiated with an Outperform at RBC Capital Mkts; tgt $40
    • Sagimet Biosciences (SGMT) initiated with an Outperform at Leerink Partners; tgt $26
    • Super Micro Computer (SMCI) initiated with an Overweight at JP Morgan; tgt $1150
    • Wells Fargo (WFC) initiated with an Accumulate at Phillip Securities

>>> US Gapping down

Gapping down
News:
  • BTAI -6% (announces $25 million registered direct offering)
  • NUVB -3.5% (Nuvation Bio and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction)
  • BYSI -2.2% (Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer)
  • APLT -1.8% (files for 14,285,714 shares of common stock by selling shareholders)
  • UUUU -1.8% (files mixed securities shelf offering)
  • CC -1.4% (names Denise Dignam as CEO, she had been interim CEO; Matthew Abbott will remain as Interim CFO as co searches for permanent CFO)
  • REGN -1.3% (FDA has issued Complete Response Letters for the Biologics License Application for odronextamab in relapsed/refractory follicular lymphoma and in R/R diffuse large B-cell lymphoma, each after two or more lines of systemic therapy)
Analyst comments:
  • BIGC -5.5% (downgraded to Underperform from Neutral at BofA Securities)
  • SMG -1.8% (downgraded to Mkt Perform from Strong Buy at Raymond James)
  • PLAY -1.6% (downgraded to Mkt Perform from Outperform at Raymond James)
  • RIVN -1.6% (downgraded to Neutral from Buy at Mizuho)
  • TSLA -1.2% (downgraded to Neutral from Buy at Mizuho)

>>> US Gapping up

Gapping up
News:
  • NKTX +12.7% (prices $240 mln offering consisting of common stock and warrants)
  • ATXS +12.4% (initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215)
  • MASI +12.1% (authorizes management to evaluate a proposed separation of its consumer business; reaffirms Q1 an FY24 guidance; Politan confirmed it nominates two independent candidates for Masimo Board)
  • MBRX +10.4% (Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial)
  • BDSX +7.2% (entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer)
  • AXSM +6.5% (announces AXS-12 achieves primary endpoint in the symphony Phase 3 trial in narcolepsy)
  • DWAC +6% (stockholders confirmed approval the proposed merger with Trump Media & Technology Group Corp)
  • ACET +2.3% (enters into an Open Market Sales Agreement to sell shares its common stock)
  • CNXC +2.2% (files for 13,166,053 share common stock offering by selling shareholders)
  • UTHR +2.1% (announces $1 billion accelerated share repurchase program)
  • BITF +1.3% (announces CEO transition; reiterates 2024 YE guidance of 21 EH/s and 21 w/TH)
  • CCO +1.2% (announces Clear Channel International B.V.'s new term loan facility and concurrent redemption of existing secured notes)
  • DIS +1.2% (Blackwells Capital believes Nelson Peltz is Not the Change Disney's Board Needs; also upgraded to Overweight from Equal Weight at Barclays)
Analyst comments:
  • GDRX +6.1% (upgraded to Overweight from Equal Weight at Wells Fargo)
  • FL +3.3% (upgraded to Outperform from In-line at Evercore ISI)
  • TPX +2.1% (upgraded to Buy from Hold at Loop Capital)
  • CAR +1.8% (upgraded to Buy from Neutral at Northcoast)
  • HUYA +1.1% (upgraded to Buy from Neutral at BofA Securities)

FT : Weight-loss drugs will not be the only blockbusters against this silent kil

Weight-loss drugs will not be the only blockbusters against this silent killer
Madrigal is the first to win approval for a treatment for a liver disease that affects one in 20

It is an ugly ailment with an ugly name. But after years of trying, the pharmaceuticals industry is getting to grips with the multibillion-dollar problem of fatty liver disease.  

This month Pennsylvania-based biotech Madrigal became the first to win approval for a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The breakthrough is badly needed. This liver disease already affects one in 20 of the world’s adults and its prevalence is rising with obesity.  

Madrigal will make the most of its head start. It is now raising $600mn to launch its pioneering drug Rezdiffra in the US. Madrigal’s market value is about $5.1bn. But Bloomberg data for analysts’ 12-month price targets would lift that by more than a third. 


That can be justified. Assume that the drug, which is set to sell for $47,400 a year, makes $4.5bn of sales in 2030. Then apply the 2.7 times 2030 EV-to-sales multiple of a group of similar biotechs listed by Visible Alpha. Discounted and adjusted for cash, that implies a Madrigal market capitalisation of about $7bn.

Yet even after it won the green light from US regulators, Madrigal’s shares are a tenth lower than they were last April. That reflects the growing excitement over the potentially wide-ranging benefits of obesity treatments, which would reduce the need for dedicated drugs. About one in five of the 105 obesity treatments being developed are also being tested for MASH, according to the Stat obesity drug tracker. 

The debate over the role of obesity drugs has not yet been settled. In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH. Impressive results also emerged for German pharma group Boehringer Ingelheim and Zealand Pharma’s survodutide.  

But MASH (which confusingly is also known as Nash or non-alcoholic steatohepatitis) is a complex disease. Often asymptomatic in its early stages, it is called a silent killer. A build-up of fatty molecules in the liver can lead to inflammation, the accumulation of scar tissues — a process called fibrosis — and potentially liver failure.

MASH has been a hard nut to crack. A phase II trial for Novo Nordisk’s semaglutide was effective at resolving inflammation but did not improve fibrosis. It is possible it requires longer treatment time. Investors are waiting for phase 3 trial results to be released later this year.

Some drugs might be effective in the early, but not the late stages of the disease. As with cancer, MASH may require combinations of drugs tailored to different patient’s needs. Despite the frenzy over weight-loss medications, those drugs shouldn’t squeeze out alternatives for tackling this nasty disease.

>>> Europe : Brokers Upgrades & Downgrades - 25th of March 2024 V3(++)

>>> Up
* Bureau Veritas Raised to Overweight at JPMorgan; PT 31 euros
* Dassault Aviation Raised to Outperform at BNPP Exane (+)
* Disney Raised to Overweight at Barclays; PT $135
* Emeis Raised to Reduce at AlphaValue/Baader
* Eurofins Scientific Raised to Buy at Kepler Cheuvreux (++)
* Ferrari PT Raised to 463 euros from 380 euros at RBC
* Gecina Raised to Buy at Goldman; PT 112 euros
* Givaudan PT Raised to 4,700 Swiss francs at Bank Vontobel
* GL Events SACA Raised to Buy at IDMidcaps; PT 22 euros (+)
* Heidelberg Materials Raised to Buy at Deutsche Bank
* Inditex Cut to Neutral at UBS; PT 47 euros (++)
* Koenig & Bauer Raised to Hold at Hauck & Aufhaeuser; PT 13 euros (+)
* LEG Immobilien Raised to Overweight at Barclays; PT 90 euros
* LEG Immobilien Raised to Neutral at Goldman; PT 70.30 euros
* Mapfre Raised to Buy at BofA; PT 2.70 euros (++)
* Orell Fuessli AG Raised to Buy at Research Partners (++)
* SGS Raised to Neutral at JPMorgan; PT 96 Swiss francs
* Tullow Raised to Buy at BofA; PT 55 pence (++)
* Volvo Car PT Raised to 48 kronor from 45 kronor at Nordea (++)
* Vossloh Raised to Buy at Deutsche Bank; PT 53 euros
* Wirtualna Polska Raised to Buy at Erste Group; PT 145 zloty

>>> Down
* Applus Cut to Hold at Kepler Cheuvreux; PT 11.10 euros (++)
* BBVA Cut to Neutral at JB Capital Markets; PT 12 euros
* Bunzl Cut to Neutral at JPMorgan; PT 3,140 pence
* Clariane Cut to Sell at AlphaValue/Baader
* Expert.ai SpA Cut to Hold at TP ICAP Midcap; PT 1.80 euros (+)
* Fondia Cut to Accumulate at Inderes; PT 8 euros
* Sage Raised to Hold at SocGen; PT 1,303 pence (+)
* SocGen Cut to Equal-Weight at Morgan Stanley; PT 29 euros
* Swiss Life Cut to Hold at Kepler Cheuvreux; PT 640 Swiss francs (++)
* TAG Immobilien Cut to Equal-Weight at Barclays; PT 11.30 euros
* Tesla Cut to Neutral at Mizuho Securities; PT $195
* TotalEnergies Cut to Hold at SocGen; PT 69 euros

>>> Initiation
* dotdigital Rated New Overweight at Cantor; PT 115 pence
* Fincantieri Rated New Hold at Stifel; PT 62 euro cents
* Huhtamaki Rated New Neutral at BNPP Exane; PT 35.40 euros (+)
* Inwido Reinstated Buy at Nordea; PT 185 kronor
* Lonza Rated New Outperform at BNPP Exane; PT 600 Swiss francs (+)
* pferdewetten.de Rated New Buy at Pareto Securities; PT 22 euros (+)
* Sinch Rated New Overweight at Cantor; PT 35 kronor
* Solaria Energia Cut to Underperform at CaixaBank BPI (+)
* Vercom Rated New Buy at Erste Group; PT 141 zloty

>>> Call
* Berenberg’s Stubbs Sees UK Equities Returning Over 10% in 2024 (++)
* Bureau Veritas, Experian Favored in Business Services: JPMorgan (+)
* Ferrari Gets Street-High Price Target at RBC on EV Opportunity
* Goldman Strategists Raise Stoxx 600 Target on Growth, Rate Cuts
* Inwido Climbs, Nordea Reinitiates at Buy as Rebound Seen (++)
* JPMorgan Says Stock Valuations Need Earnings, Dovish Policies (+)
* LEG Upgraded as Favoured German Residential Play: Barclays (++)
* Morgan Stanley Upgrades Energy Stocks on Valuation, Oil Prices
* RBC’s Calvasina Sees Equity Pullback Overdue, Melt-Up Risks (+)
* SocGen Cut at Morgan Stanley as Awaits Delivery on Strategy
* TotalEnergies Cut to Hold at SocGen, But Still a Key Holding (+)
* UCB Upgraded at Morgan Stanley on Strong Bimzelx Trajectory

FT : UK found to offer worst-value housing of advanced economies

UK found to offer worst-value housing of advanced economies
Think-tank says British pay more and get less than people in other economies with similar incomes

Britain’s housing offers the worst value for money of any advanced economy, combining high prices with old, cramped, poorly insulated buildings and long commutes, according to an influential think-tank.

The Resolution Foundation said high levels of outright home ownership obscured how bad the UK’s housing affordability was relative to other countries. Its analysis, published on Monday, showed that if all households — including owners and subsidised social renters — were renting their homes on the open market, they would have to devote 22 per cent of their spending to housing services.

Compared on this basis — by combining actual with “imputed” rents — housing consumed a larger share of spending in the UK than in any OECD country except Finland, the think-tank said.

Its findings will inflame an already heated debate over housing and planning in the run-up to the next general election, as both main parties seek to win over younger voters struggling with sky-high rents.

Rachel Reeves, shadow chancellor, last week promised to tear up a planning system she described as “the single greatest obstacle to our economic success” and reintroduce mandatory local housing targets.

Adam Corlett, principal economist at the Resolution Foundation, said the housing crisis had been “decades in the making”, with successive governments failing to build or modernise enough homes, adding: “That now has to change.”

UK households both paid more and got less for their money than in many countries with similar levels of income, the Resolution Foundation found.

In 2018, households in England had on average 38 square metres of floorspace per person — outstripped not only by their French and German counterparts, who had 43 sq metres and 46 sq metres on the latest count, but even by Japan, with 40 sq metres and residents of New York’s central city district, where the average was 43 sq metres.  


Despite long-running concerns that the UK’s housing shortage is worsened by second-home owners leaving properties empty, Britain also has one of the lowest rates of second-home ownership in Europe and one of the lowest vacancy rates in the OECD, the Resolution Foundation found.

It citied a study showing 4 per cent of British households owned second homes for their own use, compared with 9 per cent in France, 17 per cent in Finland and 22 per cent in Spain.

Meanwhile, the UK’s housing stock is easily the oldest in the EU, with almost four in 10 homes built before 1946, compared with three in 10 in France, one in four in Germany and one in 10 in Finland — with knock-on effects for energy efficiency.

It is also farther flung: 42 per cent of UK commuters travelled for more than an hour a day to reach their workplace in 2019 — well above the EU average of 37 per cent.

After adjusting for the general level of prices across each economy, people in the UK paid more for housing, relative to other goods and services, than in any other developed country — more even than in New Zealand and Australia, which have their own perennial housing crises.

“We often live in smaller, older and poorer-quality homes in the UK than households in many counterpart countries and pay a princely amount for that privilege,” the Resolution Foundation said, urging both main parties to “bring on the manifestos” to tackle the issue in the general election campaign.

WSJ : The Short Vol Trade Is Back: Why Some Investors Think It’s Driving Tranqui

The Short Vol Trade Is Back: Why Some Investors Think It’s Driving Tranquility in Markets
Investors are pouring money into derivative-income funds that sell options contracts to juice income

The stock market is calmer than it has been in years. Some worry that a popular strategy is contributing to the tranquility.

Measures of market volatility have fallen to levels last seen in 2018, while major stock indexes have climbed to repeated all-time highs. The S&P 500 is up 9.7% in 2024 and has set 20 closing records.

Investors are responding. They are seeking protection from potential losses by pouring money into what are known as derivative-income, or sometimes covered-call, exchange-traded funds that sell options contracts in a bid to juice income or boost their returns. Options are contracts that allow the holder to buy or sell shares at a predetermined price.

Assets in such funds topped $67 billion at the end of February, according to Morningstar Direct, up from about $7 billion at the end of 2020.

The funds work by primarily investing in stocks like Tesla and Meta Platforms or major indexes such as the S&P 500 and Nasdaq-100. A fraction of the fund’s assets are used to sell a call option on assets the fund already owns, in exchange for an upfront payment called a premium. The buyer of the option has the right to purchase the underlying shares at a specific price, known as a “strike.”

The funds tend to perform best in a sideways market when stocks don’t move up or down too quickly. During market slumps, they often fall less than traditional portfolios. The flip side is that investors can be locked out of potential gains when stocks stage a big rally.

Of course, the funds come with other risks. Some of the funds, like a popular Tesla ETF, offer eye-popping yields that can leave investors deeply in the red if the market turns against them. The Tesla fund is susceptible to the wild swings in the electric-vehicle maker’s stock and sells options tied to the shares to generate income. It is far from the conservative alternative that some might expect of an income-generating fund and has fallen 34% this year, compared with Tesla’s 31% decline.

Wall Street portfolio managers have chalked up the interest in these funds to investors who are eager for regular income or looking to protect against large losses after a big rally, particularly as they near retirement age.

“We are at all-time-highs, and demand for this strategy has increased. I don’t think that’s a coincidence, and I do think it’s a function of demographics,” said Eric Metz, president and chief investment officer at SpiderRock Advisors.

The rise of the funds was propelled by a 2020 Securities and Exchange Commission rule that made it easier for ETFs to buy and sell options. The largest fund in the class, the JP Morgan Equity Premium Income ETF, has about $32.8 billion in assets under management and has returned 13% since its inception in May 2020. The S&P 500 has returned 17.2% over the same period.

One possible reason for concern: The funds are a different take of the short-vol trade that blew up in spectacular fashion six years ago. A February 2018 surge in stock market turbulence led to the collapse of two volatility exchange-traded products in an episode that became known as “Volmageddon,” causing huge losses for many individual investors. The blowup rippled through the broader market and fueled further selling.

This time around, investors are skeptical that the funds will trigger a repeat.

“That option structure is relatively benign in the grand scheme of things,” said Jim Carroll, a portfolio manager at Ballast Point Wealth Management. “There’s no detonation event that’s conceivable in that structure.”

Steve Bohn, a biotech executive from Highlands Ranch, Colo., uses a strategy that is similar to the derivative-income funds. He invests in a custom bank note that sells calls to generate income and protect against downside risk. He says he became comfortable with the idea after conversations with his financial adviser.

“I just wanted to understand, what is the maximum downside and how would I feel if I lived out that worst case scenario,” he said.

Bohn, who is 57 years old, estimated his portfolio would incur a $50,000 loss if his note lost all its value. “I wouldn’t be thrilled with it, but it wouldn’t mess up my life,” he said.

The interest in derivative-income investments is part of a broader options boom that has reached new heights to kick off 2024. Traders have flocked to bold, bullish bets on Nvidia and semiconductor stocks in particular.

By one measure, trading in options has surpassed that in stocks for the first time since 2021, according to Goldman Sachs. That is based on the notional value, a measure of how much the shares underlying option contracts are worth, a figure that fluctuates with daily moves in the shares. At times, the surge in options trading has fueled concerns that the derivatives activity could stoke volatility in the broader market.

Right now, volatility could hardly be lower. The Cboe Volatility index, or VIX, known as Wall Street’s fear gauge, closed Friday at 12.91. It has closed below 16 for 97 consecutive trading days, the longest such streak since 2018, according to Dow Jones Market Data.

Some worry that the rise of option-selling funds is contributing to the calm. The fresh supply of options means dealers, who generally don’t want to take a directional bet, need to hedge their risks, said JPMorgan Chase analyst Bram Kaplan. In this situation, that means buying stock futures when markets decline and selling them as they rise, serving as a counterweight to market moves and suppressing tumult.

“Call overwriting ETFs have become a large source of volatility supply that has been increasingly weighing on market volatility levels, in our view, ” Kaplan and other analysts wrote in a research note.

Even if the rise of option-based ETFs won’t spark another Volmageddon, some fear that current market conditions make the strategy unlikely to thrive.

“I love a short-vol trade. I get interested when VIX is 20, excited when it’s at 30,” said Rob Arnott, founder and chairman of Research Affiliates. At the current level, “it’s not exactly the trade of the decade,” he said.